FDA Orange Book
Is there a generic for Bss Plus?
Bss Plus contains calcium chloride, dextrose, glutathione disulfide, magnesium chloride, potassium chloride, sodium bicarbonate, sodium chloride and sodium phosphate. Orange Book status for every listed strength, the approved generic makers, and the listed patents and exclusivities.
Source: FDA Orange Book data file dated 2026-10-09. Publisher page
No. The Orange Book lists no active FDA-approved generic (ANDA) for Bss Plus (calcium chloride, dextrose, glutathione disulfide, magnesium chloride, potassium chloride, sodium bicarbonate, sodium chloride and sodium phosphate).
Run it in Rivvi
Map Bss Plus and your other top fills to their generics
Every strength in RxNorm, with brands that have no generic flagged.
Build the mapFree to start. Opens Rivvi, the AI workspace for healthcare teams.
Bss Plus products in the Orange Book
| Form and route | Strength | Brand status | Brand TE | Active generics | Generic TE codes |
|---|---|---|---|---|---|
| solution, irrigation | 0.154MG/ML;0.92MG/ML;0.184MG/ML;0.2MG/ML;0.38MG/ML;2.1MG/ML;7.14MG/ML;0.42MG/ML | Marketed (Rx) | None | 0 | None |
NDA 018469, held by ALCON LABORATORIES INC. Active generics are ANDA products in the Orange Book prescription list with the same ingredient, dosage form, route and strength.
Questions
Is there a generic for Bss Plus?
No. The Orange Book lists no active FDA-approved generic (ANDA) for Bss Plus (calcium chloride, dextrose, glutathione disulfide, magnesium chloride, potassium chloride, sodium bicarbonate, sodium chloride and sodium phosphate).
What is the generic name for Bss Plus?
The active ingredient in Bss Plus is calcium chloride, dextrose, glutathione disulfide, magnesium chloride, potassium chloride, sodium bicarbonate, sodium chloride and sodium phosphate, per the FDA Orange Book.
What does a therapeutic equivalence code mean?
In the Orange Book, codes that start with A (such as AB) mean FDA considers the product therapeutically equivalent to the reference drug. Codes that start with B mean FDA does not, at this time, consider the product therapeutically equivalent.